Dyne Therapeutics joined PPMD for a community webinar on January 31, 2024. to present initial clinical data, released earlier this month, from the DELIVER trial of DYNE-251 in individuals with Duchenne muscular dystrophy who are amenable to exon 51 skipping. Additionally, Dyne discussed its proprietary FORCE™ platform, driving efforts to develop targeted, modern oligonucleotide therapeutics while aiming to overcome limitations in delivery to muscle tissue, with the goal of stopping or reversing disease progression.